Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 98.5 mg - capsule, hard - excipient ingredients: gelatin; croscarmellose sodium; purified water; iron oxide yellow; titanium dioxide; sodium stearylfumarate; pregelatinised maize starch; purified talc; iron oxide red; povidone; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oseltamivir strides is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir strides is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 39.4 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; purified talc; gelatin; povidone; croscarmellose sodium; iron oxide yellow; titanium dioxide; sodium stearylfumarate; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oseltamivir strides is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir strides is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - oseltamivir phosphate, quantity: 59.1 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; titanium dioxide; povidone; purified water; croscarmellose sodium; purified talc; sodium stearylfumarate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - oseltamivir strides is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,oseltamivir strides is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. jene-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: disodium edetate; purified water; yellow beeswax; indigo carmine; butylated hydroxyanisole; brilliant scarlet 4r; dl-alpha-tocopherol; gelatin; soya oil; partially hydrogenated soya oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); titanium dioxide; hydrogenated vegetable oil - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects asssociated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: soya oil; dl-alpha-tocopherol; disodium edetate; butylated hydroxyanisole; partially hydrogenated soya oil; yellow beeswax; hydrogenated vegetable oil; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); brilliant scarlet 4r; iron oxide black; titanium dioxide; purified water - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 40 mg - capsule, soft - excipient ingredients: purified water; titanium dioxide; dl-alpha-tocopherol; sorbitol solution (70 per cent) (non-crystallising); yellow beeswax; butylated hydroxyanisole; soya oil; partially hydrogenated soya oil; sunset yellow fcf; glycerol; disodium edetate; hydrogenated soya oil; gelatin - dermatane is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cyctic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 5 mg - capsule, soft - excipient ingredients: gelatin; dl-alpha-tocopherol; soya oil; titanium dioxide; purified water; yellow beeswax; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxyanisole; partially hydrogenated soya oil; hydrogenated vegetable oil; disodium edetate; glycerol - dermatane is indicated for the treatment of patients with severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of advanced prostate cancer in combination with lhrh agonist therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 400 - treatment of advanced prostate cancer in combination with lhrh agonist therapy.